Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4108230 | 0.88 | AR (0.51) | AR | |
| SCHEMBL4102257 | 0.88 | AR (0.44) | ARCASP3CASP7UTS2R | |
| SCHEMBL4108149 | 0.86 | AR (0.47) | ARCASP3CASP7 | |
| SCHEMBL4099058 | 0.86 | AR (0.42) | ARCASP3CASP7SIGMAR1 | |
| SCHEMBL4092211 | 0.86 | POLB (0.50) | ARCASP3CASP7 | |
| SCHEMBL4091539 | 0.85 | KCNQ2 (0.45) | ARSLC22A12CASP3CASP7SIGMAR1 | |
| SCHEMBL4096624 | 0.84 | AR (0.47) | ARBCHEUTS2R | |
| SCHEMBL4107428 | 0.84 | AR (0.43) | AR | |
| SCHEMBL4098535 | 0.84 | POLB (0.47) | ARCASP3CASP7 | |
| SCHEMBL4108218 | 0.84 | AR (0.41) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | SMITHKLINE BEECHMA CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | SMITHKLINE BEECHMA CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | SMITHKLINE BEECHMA CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1851204-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SmithKline Beecham Corporation (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006091592-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | NR3C1, NR3C2, NR5A1 | AR 38/4885SLC22A12 2546/4885CASP3 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.